Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 326

1.

The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma.

Hashwah H, Bertram K, Stirm K, Stelling A, Wu CT, Kasser S, Manz MG, Theocharides AP, Tzankov A, Müller A.

EMBO Mol Med. 2019 Sep 12:e10576. doi: 10.15252/emmm.201910576. [Epub ahead of print]

PMID:
31515941
2.

How to resolve a clinical and molecular puzzle: concomitant monoclonal gammopathy of undetermined significance (MGUS) with neutrophilia and clonal hematopoiesis of indeterminate potential (CHIP).

Haefliger S, Juskevicius D, Höller S, Buser U, Dirnhofer S, Tzankov A.

Ann Hematol. 2019 Oct;98(10):2431-2432. doi: 10.1007/s00277-019-03786-9. Epub 2019 Aug 20. No abstract available.

PMID:
31432215
3.

Our approach to bone marrow biopsies in cytopenia.

Le Clef Q, Menter T, Tzankov A.

Pathol Res Pract. 2019 Jul;215(7):152447. doi: 10.1016/j.prp.2019.152447. Epub 2019 May 9. Review.

PMID:
31101575
4.

Cluster Analysis According to Immunohistochemistry is a Robust Tool for Non-Small Cell Lung Cancer and Reveals a Distinct, Immune Signature-defined Subgroup.

Sterlacci W, Fiegl M, Juskevicius D, Tzankov A.

Appl Immunohistochem Mol Morphol. 2019 May 1. doi: 10.1097/PAI.0000000000000751. [Epub ahead of print]

PMID:
31058655
5.

Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.

Cascione L, Rinaldi A, Bruscaggin A, Tarantelli C, Arribas AJ, Kwee I, Pecciarini L, Mensah AA, Spina V, Chung EYL, Terzi di Bergamo L, Dirnhofer S, Tzankov A, Miranda RN, Young KH, Traverse-Glehen A, Gaidano G, Swerdlow SH, Gascoyne R, Rabadan R, Ponzoni M, Bhagat G, Rossi D, Zucca E, Bertoni F.

Haematologica. 2019 Apr 24. pii: haematol.2018.214957. doi: 10.3324/haematol.2018.214957. [Epub ahead of print]

6.

Transformation of a splenic marginal zone lymphoma into classic Hodgkin lymphoma.

Menter T, Dirnhofer S, Tzankov A.

J Clin Pathol. 2019 May;72(5):391-392. doi: 10.1136/jclinpath-2018-205678. Epub 2019 Feb 27. No abstract available.

PMID:
30814198
7.

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.

Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH.

Cancer Immunol Res. 2019 Apr;7(4):644-657. doi: 10.1158/2326-6066.CIR-18-0439. Epub 2019 Feb 11.

PMID:
30745366
8.

ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis.

Menter T, Ballova V, Caspar C, Wolff T, Kasenda B, Singer G, Juskevicius D, Tzankov A, Dirnhofer S.

Virchows Arch. 2019 Jun;474(6):763-767. doi: 10.1007/s00428-019-02531-x. Epub 2019 Jan 26.

PMID:
30685783
9.

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.

Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH.

Mod Pathol. 2019 Jun;32(6):741-754. doi: 10.1038/s41379-018-0193-5. Epub 2019 Jan 21.

PMID:
30666052
10.

Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Bianchi M, Heim D, Lengerke C, Halter J, Gerull S, Kleber M, Tsakiris DA, Passweg J, Tzankov A, Medinger M.

Ann Hematol. 2019 Apr;98(4):971-977. doi: 10.1007/s00277-018-3577-1. Epub 2018 Dec 12.

PMID:
30542943
11.

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14.

Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides AP, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RC; Swiss Group for Clinical Cancer Research (SAKK).

Haematologica. 2019 Apr;104(4):710-716. doi: 10.3324/haematol.2018.200014. Epub 2018 Nov 8.

12.

RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall.

Menter T, Lundberg P, Wenzel F, Dirks J, Fernandez P, Friess D, Dirnhofer S, Tzankov A.

Pathobiology. 2019;86(2-3):162-166. doi: 10.1159/000493688. Epub 2018 Nov 5.

PMID:
30396184
13.

TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells.

Burkhard R, Keller I, Arambasic M, Juskevicius D, Tzankov A, Lundberg P, Bruggmann R, Dirnhofer S, Radpour R, Novak U.

Haematologica. 2019 Apr;104(4):766-777. doi: 10.3324/haematol.2018.201590. Epub 2018 Oct 31.

14.

T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights.

Le Clef Q, Ortega-Sanchez G, Dirnhofer S, Tzankov A.

Leuk Lymphoma. 2019 May;60(5):1320-1323. doi: 10.1080/10428194.2018.1520993. Epub 2018 Oct 10. No abstract available.

PMID:
30301393
15.

[Ectopic thymic tissue and ectopic thymic tumors].

Marx A, Rüdiger T, Rößner E, Tzankov A, de Montpréville VT, Rieker RR, Ströbel P, Weis CA.

Pathologe. 2018 Sep;39(5):390-397. doi: 10.1007/s00292-018-0485-z. Review. German.

PMID:
30159601
16.

Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Menter T, Tzankov A.

Virchows Arch. 2019 Apr;474(4):497-509. doi: 10.1007/s00428-018-2438-6. Epub 2018 Aug 21.

PMID:
30132131
17.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H.

J Clin Invest. 2018 Nov 1;128(11):4912-4923. doi: 10.1172/JCI120612. Epub 2018 Sep 24.

18.

High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease.

Kraft S, Bollinger N, Bodenmann B, Heim D, Bucher C, Lengerke C, Kleber M, Tsakiris DA, Passweg J, Tzankov A, Medinger M.

Bone Marrow Transplant. 2019 Apr;54(4):540-548. doi: 10.1038/s41409-018-0293-3. Epub 2018 Aug 14.

PMID:
30108323
19.

Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.

Juskevicius D, Jucker D, Dietsche T, Perrina V, Rufle A, Ruiz C, Dirnhofer S, Tzankov A.

Lab Invest. 2018 Nov;98(11):1487-1499. doi: 10.1038/s41374-018-0096-6. Epub 2018 Aug 7.

PMID:
30087457
20.

Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016.

Tzankov A, Kremer M, Leguit R, Orazi A, van der Walt J, Gianelli U, Hebeda KM.

Ann Hematol. 2018 Nov;97(11):2117-2128. doi: 10.1007/s00277-018-3436-0. Epub 2018 Aug 6.

21.

Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.

Hebeda KM, Tzankov A, Boudova L, Saft L, Hasserjian RP, de Boer M, Fend F, Orazi A, Leguit R.

Pathobiology. 2019;86(1):62-75. doi: 10.1159/000489678. Epub 2018 Jul 6.

22.

Localized pain-causing JAK2-V617F-positive myeloproliferation with normal peripheral blood values.

Gerlach MM, Arranto C, Dirnhofer S, Tzankov A.

Ann Hematol. 2018 Nov;97(11):2265-2266. doi: 10.1007/s00277-018-3363-0. Epub 2018 May 16. No abstract available.

PMID:
29766235
23.

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH.

Neoplasia. 2018 Jun;20(6):574-593. doi: 10.1016/j.neo.2018.03.002. Epub 2018 May 4.

24.

Diagnostic and prognostic impact of mucin 1-6 expression in non-small cell lung cancer.

Sterlacci W, Fiegl M, Veits L, Tzankov A.

Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):187-191. doi: 10.4103/IJPM.IJPM_678_17.

25.

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.

Klepsch V, Hermann-Kleiter N, Do-Dinh P, Jakic B, Offermann A, Efremova M, Sopper S, Rieder D, Krogsdam A, Gamerith G, Perner S, Tzankov A, Trajanoski Z, Wolf D, Baier G.

Nat Commun. 2018 Apr 18;9(1):1538. doi: 10.1038/s41467-018-04004-2.

26.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R.

Eur J Cancer. 2018 Jun;96:6-16. doi: 10.1016/j.ejca.2018.03.012. Epub 2018 Apr 13.

PMID:
29660598
27.

The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma.

Stelling A, Hashwah H, Bertram K, Manz MG, Tzankov A, Müller A.

Blood. 2018 May 17;131(20):2235-2246. doi: 10.1182/blood-2017-10-810630. Epub 2018 Apr 3.

28.

Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.

Menter T, Tzankov A.

Front Oncol. 2018 Mar 7;8:54. doi: 10.3389/fonc.2018.00054. eCollection 2018. Review.

29.

High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.

Pillonel V, Juskevicius D, Ng CKY, Bodmer A, Zettl A, Jucker D, Dirnhofer S, Tzankov A.

Leukemia. 2018 Nov;32(11):2412-2426. doi: 10.1038/s41375-018-0082-4. Epub 2018 Feb 28.

30.

Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.

Gerlach MM, Lundberg P, Halter J, Arranto C, Wenzel F, Dirnhofer S, Tzankov A.

Leuk Lymphoma. 2018 Aug;59(8):1994-1997. doi: 10.1080/10428194.2017.1406087. Epub 2017 Dec 3. No abstract available.

PMID:
29199511
31.

Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis.

Wittig BM, Sabat R, Holzlöhner P, Witte-Händel E, Heilmann K, Witte K, Triebus J, Tzankov A, Laman JD, Bokemeyer B, Terracciano L, Schwärzler C, Kohler H, Volkmer R, Loddenkemper C, Wolk K, Hoffmann U, Günthert U.

Mucosal Immunol. 2018 May;11(3):846-860. doi: 10.1038/mi.2017.98. Epub 2017 Nov 29.

PMID:
29186109
32.

CASTLE tumor of the parotid: First documented case, literature review, and genetic analysis of the cancer.

Wong EHC, Tetter N, Tzankov A, Muller L.

Head Neck. 2018 Jan;40(1):E1-E4. doi: 10.1002/hed.24985. Epub 2017 Nov 9. Review.

PMID:
29120527
33.

Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study.

Magaton IM, Tzankov A, Krasniqi F, Rottenburger C, Zanetti-Daellenbach R, Grendelmeier P, Heinzelmann-Schwarz V, Mayr M, Schwab FD.

Case Rep Oncol. 2017 Oct 5;10(3):876-884. doi: 10.1159/000480696. eCollection 2017 Sep-Dec.

34.

Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.

Juskevicius D, Müller A, Hashwah H, Lundberg P, Tzankov A, Menter T.

Leuk Lymphoma. 2018 Jul;59(7):1710-1716. doi: 10.1080/10428194.2017.1387903. Epub 2017 Oct 18.

PMID:
29043881
35.

PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma.

Haefliger S, Bihl M, Krasniqi F, Tzankov A.

Ann Hematol. 2018 Feb;97(2):355-357. doi: 10.1007/s00277-017-3145-0. Epub 2017 Oct 3. No abstract available.

PMID:
28975389
36.

Lymphomdiagnostik durch den Pathologen – von der Morphologie über den Immunphänotyp bis zur Genanalyse.

Menter T, Tzankov A, Dirnhofer S.

Ther Umsch. 2017 Sep;74(4):197-203. doi: 10.1024/0040-5930/a000904. Review. German. No abstract available.

PMID:
28950777
37.

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, Montes-Moreno S, Dybkær K, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH.

Br J Cancer. 2017 Nov 21;117(11):1685-1688. doi: 10.1038/bjc.2017.345. Epub 2017 Sep 26.

38.

Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer.

Weixler B, Renetseder F, Facile I, Tosti N, Cremonesi E, Tampakis A, Delko T, Eppenberger-Castori S, Tzankov A, Iezzi G, Kettelhack C, Soysal SD, von Holzen U, Spagnoli GC, Terracciano L, Tornillo L, Droeser RA, Däster S.

Cell Oncol (Dordr). 2017 Dec;40(6):609-619. doi: 10.1007/s13402-017-0348-2. Epub 2017 Sep 21.

PMID:
28936810
39.

Response to the letter to the editor of Lambros et al.

Sterlacci W, Tzankov A, Savic S.

Virchows Arch. 2017 Nov;471(5):687-688. doi: 10.1007/s00428-017-2230-z. Epub 2017 Sep 7. No abstract available.

PMID:
28879608
40.

Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments.

Muraro MG, Muenst S, Mele V, Quagliata L, Iezzi G, Tzankov A, Weber WP, Spagnoli GC, Soysal SD.

Oncoimmunology. 2017 May 30;6(7):e1331798. doi: 10.1080/2162402X.2017.1331798. eCollection 2017.

41.

Broken heart by T-prolymphocytic leukemia.

Arranto C, Tzankov A.

Blood. 2017 Aug 3;130(5):691. doi: 10.1182/blood-2017-05-784363. No abstract available.

42.

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH.

Leukemia. 2018 Feb;32(2):353-363. doi: 10.1038/leu.2017.222. Epub 2017 Jul 12.

43.

Beneficial role of increased FOXP3+ regulatory T-cells in acute myeloid leukaemia therapy response.

Menter T, Kuzmanic B, Bucher C, Medinger M, Halter J, Dirnhofer S, Tzankov A.

Br J Haematol. 2018 Aug;182(4):581-583. doi: 10.1111/bjh.14819. Epub 2017 Jun 27. No abstract available.

PMID:
28653378
44.

AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH.

Am J Pathol. 2017 Aug;187(8):1700-1716. doi: 10.1016/j.ajpath.2017.04.009. Epub 2017 Jun 13.

45.

A pattern-based approach to reactive lymphadenopathies.

Tzankov A, Dirnhofer S.

Semin Diagn Pathol. 2018 Jan;35(1):4-19. doi: 10.1053/j.semdp.2017.05.002. Epub 2017 May 25. Review.

PMID:
28619469
46.

Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease.

Matter MS, Bihl M, Juskevicius D, Tzankov A.

Virchows Arch. 2017 Oct;471(4):545-547. doi: 10.1007/s00428-017-2173-4. Epub 2017 Jun 9. No abstract available.

PMID:
28597077
47.

Genetic background and evolution of relapses in aggressive B-cell lymphomas.

Juskevicius D, Dirnhofer S, Tzankov A.

Haematologica. 2017 Jul;102(7):1139-1149. doi: 10.3324/haematol.2016.151647. Epub 2017 May 29. Review.

48.

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.

Sterlacci W, Fiegl M, Gugger M, Bubendorf L, Savic S, Tzankov A.

Virchows Arch. 2017 Jul;471(1):49-55. doi: 10.1007/s00428-017-2131-1. Epub 2017 May 20.

PMID:
28528511
49.

Mutational landscape of B-cell post-transplant lymphoproliferative disorders.

Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, Naresh KN.

Br J Haematol. 2017 Jul;178(1):48-56. doi: 10.1111/bjh.14633. Epub 2017 Apr 17.

PMID:
28419429
50.

Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas.

Menter T, Trivedi P, Ahmad R, Flora R, Dirnhofer S, Tzankov A, Naresh KN.

Am J Clin Pathol. 2017 Mar 1;147(3):292-300. doi: 10.1093/ajcp/aqw208.

PMID:
28395058

Supplemental Content

Loading ...
Support Center